BrainsWay (BWAY) Analyst & Investor Day 2025 summary

Financial performance and business model evolution

• Achieved $13.5M in Q3 revenue, up 29% YoY, with 75% gross margin and $2M adjusted EBITDA, up 81%.

• Remaining performance obligation reached $65M, up 37% YoY, with 70% of new deals as multi-year leases.

• Recurring revenue grew 34% YoY, outpacing non-recurring at 23%, shifting to a high-margin ARR model.

• 10 consecutive quarters of positive free cash flow, $71M in cash, no debt, and a $7M annualized EBITDA run rate.

• 2025 revenue guidance of $52M is fully supported by pipeline and recurring base.

Strategic growth drivers and investments

• Organic growth driven by new clinical protocols, expanded indications, and increased utilization.

• Strategic minority investments in mental health clinics, including Stella MSO, to expand access and recurring revenue with minimal OpEx.

• Four minority investments completed in 2023, with plans for up to 10 new investments and broader enterprise rollout.

• Valor Equity Partners' involvement signals platform scalability and operational support.

• International expansion underway, with growing demand in Asia-Pacific, Europe, Middle East, and Latin America.

Growth strategy and business development

• Plans to highlight growth strategy and discuss strategic investment in Stella MSO, a management services organization for mental health clinics in the US and Israel.

• Focus on expanding access to Deep TMS, a noninvasive brain stimulation treatment for mental health and addiction conditions.

• Emphasis on increasing global awareness and broadening the reach of Deep TMS technology.

• Ongoing clinical studies aim to expand indications for Deep TMS in psychiatric, neurological, and addiction disorders.